NESS ZIONA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL) ("Sol-Gel" or the "Company"), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will host an Analyst and Investor Day on Thursday, July 25, 2019 from 8:30 a.m. EST to 11:00 a.m. EST at the Maxwell Hotel in New York City. 

• Linda Stein Gold, MD., Director of Dermatology Clinical Research at Henry Ford Health System
• Jeffrey Sugarman, MD., Ph.D., Medical Director Northern California Medical Associates, Assoc. Clinical Professor, University of California, San Francisco
• Mori Arkin, Chairman of The Board of Directors
• Alon Seri-Levy, Ph.D., Co-Founder and Chief Executive Officer
• John Vieira, U.S. Head of Commercialization

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel's current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. For additional information, please visit www.sol-gel.com.